Breast Cancer Research and Treatment **42**: 291-292, 1997.
© 1997 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 42

Alaimo C 23
Alonso MC 83
Amoils KD 95
Auer G 207

Bearzatto A 103
Benedusi-Pagliano E 227
Betz NA 125,137
Bezwoda WR 95
Bhalla K 73
Bonetti A 23

Caduff-Joos R 253
Cafiero F 183
Case LD 265
Catalano MG 227
Cetto GL 23
Chinchilli VM 1
Chung HC 65
Comba A 227

Dalton WS 7
Davis S 187
De Marco C 103
Díez-Gibert O 83
Dirix LY 165
Dorr RT 7

Engel G 207
Enomoto K 57
Evans MC 15

Fattaey HK 125,137
Fattovich G 23
Fazzari A 227
Fortunati N 227
Frairia R 227
Fujiwara K 57

George J 215
Gibbs EE 15
Gimotty P 215
Gipponi M 183
Gornati D 103
Griffith CDM 283

Haile RW 243
Haller U 253
Hislop TG 235
Hoen H 265
Holdaway IM 15
Hopkins KD 15
Huang Y 73
Hübner K 149

Ibrado AM 73
Ikeda T 57
Imoto S 57
Ishimura Y 57
Ito H 173
Ito K 173
Iwase H 173
Iwase T 87
Iwata H 173

Jain M 43
Johnson TC 125,137

Kan L 235
Kasumi F 87
Khan S 275
Kim BS 65
Kim JH 65
Kitajima M 57
Kobayashi S 173
Kostner GM 195
Kumar R 1
Kuss JT 265

Landucci M 183
Lee KB 65
Lee KS 65
Lethaby A 15
Libura J 165
Libura M 165
Lim T 15
Linder C 207
Linder S 207
Lipton A 1

Masamura S 215
Masaoka A 173
Mason BH 15
Massobrio M 227
Mesía R 83
Micciolo R 23
Miller AB 43
Min JS 65
Mitani F 57
Molino A 23
Moos PJ 125
Mosley K 7
Muss HB 265

Nakamura T 173
Narvaez CJ 31
Navarro MA 83
Nawabi A 73
Nortilli R 23

O'Neill PJ 165
Ojeda B 83

Paganini-Hill A 243
Paulsen AQ 137
Pavanel F 23
Pelosi G 23
Perry RH 283
Piubello Q 23
Potter JD 187
Pronzato P 183

Queirolo P 183

Rageth C 253
Rajan PB 283
Rajasoorya C 15
Ray S 73
Reed JC 73
Revelli A 227
Rha SY 65
Roh JK 65

Ross JA 187
Rousseau E 235
Rueda A 83

Salmon SE 7
Santen RJ 215
Santner SJ 215
Sauerbrei W 149
Sbverveglieri M 227
Schmidt H 195
Schmoor C 149
Schooler B 15
Schumacher M 149
Scott DJ 283
SenGupta S 113
Severson RK 187
Siemiatycki J 243
Silvestrini R 103
Simboli-Campbell M 31
Sperotto L 23
Stanford JL 187
Sterns EE 113
Strander H 207
Stranzl A 195

Tada T 87
Takahashi K 87
Tang C 73
Taylor CW 7
Tenniswood M 31
Thompson WD 243
Toyama T 173
Trief PM 275
Turazza M 23

Uchida Y 87
Unger C 253
Ursin G 243

Vaira F 183
van Dam P 165
Van Marck E 165
Van Oosterom AT 165
VanWeelden K 31
Vermeulen PB 165
Vigani A 183

Walt H 253
Wels J 31
Westhoff BA 125,137
Wight E 253
Winkler R 195
Witte JS 243
Witters LM 1
Worth AJ 235
Wyss P 253
Wyss-Desserich M-T 253

Yamashita H 173
Yamashita T 173
Yoshimoto M 87

Zaffaroni N 103
Zaloznik AJ 121
Zee B 113

Breast Cancer Research and Treatment **42**: 293-296, 1997.
© 1997 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 42

angiogenesis
by MVD, and interstitial clearance rate, in prognosis 113-120
microvessel density measure — effects of investigator experience, field size 165-172
no correlation of MVD with stromelysin-3 transcripts 207-213
antiestrogens
see tamoxifen
apoptosis
Bcl-2 protein and estrogen receptor in prognosis 173-181
by taxol, inhibition by estrogen-induced Bcl-2 in MCF-7 73-81
in MCF-7 cells with vitamin D analogs 31-41
induced by sialoglycopeptide CeReS-18, calcium sensitivity 137-148

Bax protein
increased Bcl-2/Bax ratio with estrogen inhibits taxol-induced apoptosis 73-81
Bcl-2 protein
and estrogen receptor in prognosis 173-181
induction by estrogen and inhibition of taxol-induced apoptosis 73-81
beta carotene
in diet — decreased risk of dying from breast cancer 43-55
bilateral premenopausal breast cancer
case-control study of diet 243-251
bone marrow micrometastases
detected by pooled monoclonal antibodies — no effect on prognosis 23-30
higher when sampled during breast surgery 23-30
breast self-examination (BSE)
seasonal variations in self-detection of breast cancer 187-192
BT-20 human breast cancer cells
cycle arrest and apoptosis by CeReS-18 sialoglycopeptide 137-148
mitogen stimulus overcome by CeReS-18 sialoglycopeptide 125-136
BT474 human breast cancer cells
inhibition by HER-2/neu antibody plus tamoxifen 1-5

calcium
in cell cycle arrest and apoptosis by sialoglycopeptide CaReS-18 137-148
in diet — decreased risk of dying from breast cancer 43-55
catechol estrogens
E2 hydroxylases and E1 sulfatase in breast cancer vs. normal 57-64
CeReS-18 sialoglycopeptide
calcium-sensitive cell cycle arrest and apoptosis 137-148
inhibition of MCF-7 and BT-20 cells overcomes mitogens 125-136
chemotherapy
chemosensitizers quinine and verapamil rescue CVAD failures 7-14
ifosfamide/vinorelbine in anthracycline-resistant metastatic disease 183-186
lonidamine potentiation of cisplatin and epidoxorubicin (cell lines) 103-112
cholesterol
regulation of LDL receptor in breast cancer cell lines 195-205
circannual rhythms
in mammotrophic hormones, breast cancer vs. normal 15-22
cisplatin
potentiation by lonidamine (with epidoxorubicin) in cell lines 103-112
cortisol
seasonal variation differences, normal vs. breast cancer 15-22

detection
seasonal variations in self-detection of breast cancer 187-192
diet
case-control study in bilateral premenopausal breast cancer 243-251

dietary variables
effects on breast cancer characteristics and survival 43-55
DNA flow cytometry
$S+G_2/M$ phase in pre-menopausal node-negative prognosis 253-263
drug resistance
chemosensitizers quinine and verapamil rescue CVAD failures 7-14
drug response
P-glycoprotein as an intermediate endpoint (FAC induction therapy) 65-72
ductal carcinoma in situ (DCIS)
Bcl-2 protein and estrogen receptor in subtypes 173-181
p53 protein associated with comedo subtype, high grade 293-290

endocrine therapy
tamoxifen as initial endocrine therapy for endocrine-naive metastatic disease 265-274
epidermal growth factor (EGF)
higher in saliva, lower in plasma, in breast cancer vs. normal 83-86
interference with mitogenic activity by sialoglycopeptide CaReS-18 125-136
epidoxorubicin
potentiation by lonidamine (with cisplatin) in cell lines 103-112
estrogen
interference with mitogenic activity by sialoglycopeptide CaReS-18 125-136
estrogen metabolism
E2 hydroxylases and E1 sulfatase in breast cancer vs. normal 57-64
estrogen receptor
and Bcl-2 in prognosis 173-181
and presence of SHBG receptor on breast cancer cells 227-234
and TGF-β1 mRNAs in 89 breast cancers 95-101
downregulation by vitamin D analogs 31-41
in breast cancer — effect of dietary variables 43-55
in pre-menopausal node-negative prognosis 253-263
status vs. levels of LDL receptor and its regulation 195-205
estrogen uptake
evidence for very high affinity mechanism in breast tumor cells 215-226
estrogens
increased Bcl-2 and decreased taxol-induced apoptosis 73-81
ethnicity
Hispanic women present younger and more advanced than whites 121-124

familial breast cancer
case-control study of diet and risk of bilateral premenopausal breast cancer 243-251
fat intake
may reduce risk of bilateral premenopausal breast cancer 243-251
fibroblast growth factor, basic (b-FGF)
interference with mitogenic activity by sialoglycopeptide CaReS-18 125-136
flow cytometry
$S+G_2/M$ phase in pre-menopausal node-negative prognosis 253-263

galactography
by MRI in a patient with nipple discharge 87-90
growth hormone
similar seasonal variation in breast cancer vs. normal 15-22

HER-2/*neu*
antibody, plus tamoxifen, inhibiting BT474 cells 1-5
histologic grade
in pre-menopausal node-negative prognosis 253-263

ifosfamide
with vinorelbine in anthracycline-resistant metastatic disease 183-186
immunotherapy
HER-2/neu antibody plus tamoxifen on BT474 cells 1-5
induction chemotherapy
P-glycoprotein as an intermediate endpoint of response 65-72

insulin-like growth factors (IGFs)
IGF-I seasonal variation differences, normal vs. breast cancer 15-22
interference with mitogenic activity by sialoglycopeptide CaReS-18 125-136
intraductal cancer
see ductal carcinoma in situ (DCIS)
invasion
no correlation of stromelysin-3 mRNA with angiogenesis (MVD) 207-213

LDL (low-density lipoprotein) receptor
mRNA 3-5 times higher in ER– cells; depends on protein kinase C 195-205
lonidamine
potentiation of cisplatin and epidoxorubicin treatment (cell lines) 103-112
lymphatics
macromolecular interstitial clearance vs. other prognostic factors 113-120

magnetic resonance galactography
method and case report 87-90
mammography
density — post-screen-detected breast cancer characteristics 235-242
matrix metalloproteinases
no correlation of stromelysin-3 mRNA with angiogenesis (MVD) 207-213
MCF-7 human breast cancer cells
inhibition and apoptosis by vitamin D analogs 31-41
cycle arrest and apoptosis by CeReS-18 sialoglycopeptide 137-148
increased Bcl-2/Bax ratio with estrogen inhibits taxol-induced apoptosis 73-81
lonidamine potentiation of cisplatin and epidoxorubicin 103-112
mitogen stimulus overcome by CeReS-18 sialoglycopeptide 125-136
melatonin
seasonal variation reversed in breast cancer vs. normal 15-22
metastatic breast cancer
ifosfamide/vinorelbine in anthracycline-resistant disease 183-186
tamoxifen as initial endocrine therapy for endocrine-naive patients 265-274
microvessel density
in prognosis — effects of investigator experience, field size 165-172
no correlation with stromelysin-3 transcripts 207-213

nipple discharge
use of MRI galactography 87-90
nitrosomethyl urea (NMU) rat mammary tumors
evidence for very high affinity estrogen uptake mechanism 215-226
Nottingham Prognostic Index
in comparison and validation of classification schemes 149-163

P-glycoprotein
as an intermediate endpoint of induction chemotherapy (FAC) response 65-72
p53 protein
in DCIS, associated with comedo subtype and high grade 283-290
postmenopausal tissue estrogen levels
evidence for very high affinity mechanism in breast tumor cells 215-226
progesterone receptor
in breast cancer — effect of dietary variables 43-55
in pre-menopausal node-negative prognosis 253-263
prognostic factors
angiogenesis (MVD) 113-120
Bcl-2 protein and estrogen receptor 173-181
bone marrow micrometastases — no effect on outcome 23-30
comparison and validation methods for classification schemes 149-163
ER/PgR, S+G_2/M phase, histologic grade in premenopausal node-negative disease 253-263
macromolecular interstitial clearance by lymphatics 113-120
microvessel density — effects of investigator experience, field size 165-172
new classification schemes 149-163
programmed cell death
see apoptosis

prolactin
no seasonal variation in breast cancer or normal 15-22
proliferation rate
by cytosol thymidine kinase — reduced in presence of SHBG receptor 227-234
protein kinase C
and regulation of LDL receptor in breast cancer cells 195-205
psychosocial morbidity
predictors and their assessment by surgical oncologists 275-281

quinine
as chemosensitizer for CVAD chemotherapy 7-14

race
see ethnicity
regression tree analysis
in development of new prognostic classification schemes 149-163
retinoblastoma (Rb) protein
hypophosphorylated in cell cycle arrest by vitamin D analogs 31-41
RT-PCR
for ER and TGF-β1 mRNAs in 89 breast cancers 95-101

screening
post-screen-detected breast cancer characteristics 235-242
seasonal variations
in mammotrophic hormones, breast cancer vs. normal 15-22
in self-detection of breast cancer 187-192
sex steroid binding protein (SBP, SHBG) receptor
and reduced proliferation rate in breast cancer 227-234
sialoglycopeptide
see CaReS-18 sialoglycopeptide
socioeconomic status
Hispanic women present younger and more advanced than whites 121-124
surgical oncologists
and assessment of predictors of psychosocial morbidity 275-281

T47D human breast cancer cells
lonidamine potentiation of cisplatin and epidoxorubicin 103-112
tamoxifen
as initial endocrine therapy for endocrine-naive metastatic breast cancer 265-274
with HER-2/neu antibody inhibiting BT474 cells 1-5
taxol
induced apoptosis in MCF-7 prevented by estrogen via Bcl-2 73-81
thyrotropin (TSH)
no seasonal variation in breast cancer or normal 15-22
transforming growth factor β1 (TGF-β1)
and ER mRNAs in 89 breast cancers 95-101
tumor suppressor genes
p53 protein associated with comedo subtype, high grade in DCIS 293-290

validation
of prognostic factor classification schemes 149-163
verapamil
as chemosensitizer for CVAD chemotherapy 7-14
vinorelbine
with ifosfamide in anthracycline-resistant metastatic disease 183-186
vitamin C
in diet — decreased risk of dying from breast cancer 43-55
vitamin D analogs
1,25-dihydroxy D_3 vs. low-calcemic EB108 — MCF-7 inhibition and apoptosis 31-41